LEPROSY

(Diagnosis, Diagnostics, Immunodiagnosis, Immunodiagnostics,  Pathogenesis, Vaccines & Drugs)

4112.      AL-Qubati Y, AL-Kubatia A S:Multidrug therapy-the pathway for global leprosy elimination. Indian J Lepr 2000, 72(4), 477-90.(013112) July1, 2001.

4113.      Brunet RC, Struchiner CJ, Loinaz A. A method for estimating time dependent intervention benefits under arbitrarily varying age and exogenous components of hazard. Lifetime Data Anal  2001 Dec;7(4):377-92

4114.      Cooke GS, Hill AV. Genetics of  susceptibility to human infectious disease. Nat Rev Genet  2001 Dec;2(12):967-77

4115.      Ghorpade A, Ramanan C: Primary penil tuberculoid leprosy. Indian J Lepr 2000, 72(4),499-500.(013154). July1, 2001.

4116.      K, Kashiwabara Y. Multidrug resistant Mycobacterium leprae from patients  with leprosy. Antimicrob Agents Chemother  2001 Dec;45(12):3635-9

4117.      LM, Valdez R, Sordelli DO, Aversa G, Modlin RL, Sieling PA. Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol  2001 Nov 15;167(10):5719-24

4118.      PN. Detection of Mycobacterium leprae DNA by polymerase chain reaction in the blood of individuals, eight years after completion of anti-leprosy therapy. Mem Inst Oswaldo Cruz  2001 Nov;96(8):1129-33

4119.    Vekatesan K, Nirmal Deo, Girdhar A, Girdhar B K: Multiple dose pharmacokinetics of clofazimine in leprosy. Indian J Pharmac 2001,33(2), 136-7. (016536) Aug 16, 2023